Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2977–3000 of 3,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension, Pulmonary
Interventions: PF-00489791, placebo, sildenafil; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Phoenix, Arizona • Gainesville, Florida • Omaha, Nebraska + 2 more

Conditions: Hypertension
Interventions: losartan potassium hydrochlorothiazide; Drug
Lead sponsor: Roxane Laboratories; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Improving Blood Pressure Control
Interventions: CONTROL- Usual & Customary Health Fair Follow-up, Health Fair + TECH [Text Messaging + Home Blood Pressure Monitoring], Heal th Fair + TECH [Text Messaging + Home Blood Pressure Monitoring] + Social Network Support (SNS); Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 21 Years and older · Male only
Enrollment: 166 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypertension, Self-Management, Technology, Quality of Life
Interventions: OPTIMA-BP Intervention; Behavioral
Lead sponsor: Case Western Reserve University; Other
Eligibility: 50 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Stroke, Hypertension, Home Blood Pressure Monitoring, Implementation Research
Interventions: Group medical visits and home blood pressure monitoring; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 35 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cataracts, Retina Surgery, Glaucoma, Any Condition That Requires Ophthalmic Drops
Interventions: Not listed
Lead sponsor: Alexander Eaton; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: Pre-Eclampsia
Interventions: recombinant human relaxin; Drug
Lead sponsor: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 2
States / cities: Lexington, Kentucky • Cincinnati, Ohio

Conditions: Elevated Blood Pressure, Hypertension
Interventions: Dietitian-Assisted DASH groceries, Self-directed shopping; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 100 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hypertension
Interventions: olmesartan, hydrochlorothiazide, amlodipine, hydrochlorothiazide (HCTZ) or olmesartan; Drug
Lead sponsor: The Louis & Rachel Rudin Foundation; Other
Eligibility: 40 Years to 85 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 5
States / cities: The Bronx, New York

Conditions: Hypertension
Interventions: Acetaminophen, NSAID; Drug
Lead sponsor: St. Louis University; Other
Eligibility: 14 Years to 50 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Gastrointestinal Hemorrhage, Portal Hypertension
Interventions: Thalidomide; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hypertension
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 40 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Food Insecurity, Hypertension
Interventions: Food as Medicine Program, Survey; Behavioral · Other
Lead sponsor: Alison Gustafson; Other
Eligibility: 18 Years to 64 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Floyd, Kentucky

Conditions: Intra-Abdominal Hypertension, Inguinal Hernia
Interventions: Accuryn Monitoring System; Device
Lead sponsor: Antonios Likourezos; Other
Eligibility: 18 Years to 65 Years
Enrollment: 21 participants
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Hypertension, Blood Pressure
Interventions: REDUCE-BP Intervention; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 49,210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: Placebo, Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule, Amlodipine 10 mg capsule, Aliskiren/amlodipine 150/5 mg tablet, Aliskiren/amlodipine 150/10 mg tablet, Aliskiren/amlodipine 300/5 mg tablet, Aliskiren/amlodipine 300/10 mg tablet; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 2,694 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypertension in Pregnancy, Gestational Diabetes, Cervical Dysplasia
Interventions: Postpartum follow up card, Control; Behavioral · Other
Lead sponsor: Medstar Health Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 157 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Preeclampsia Postpartum
Interventions: Aspirin 81 mg, Placebo; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Sleep Apnea, Obstructive, Primary Open-angle Glaucoma
Interventions: SENSIMED Triggerfish®; Device
Lead sponsor: Sensimed AG; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Heart Failure, Hypertension, Pulmonary
Interventions: Beetroot juice; Dietary Supplement
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2023
U.S. locations: 2
States / cities: Indianapolis, Indiana • St Louis, Missouri

Conditions: Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Hypertension
Interventions: Device guided breathing RESPeRATE, Isometric hand grip Zona Plus; Device
Lead sponsor: University of Michigan; Other
Eligibility: 21 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pulmonary Arterial Hypertension
Interventions: Macitentan 10 mg, Placebo; Drug
Lead sponsor: Actelion; Industry
Eligibility: 12 Years and older
Enrollment: 226 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 7
States / cities: Los Angeles, California • Palo Alto, California • Atlanta, Georgia + 4 more

Conditions: Angina, Pulmonary Arterial Hypertension
Interventions: Ranolazine; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

Bioequivalency Study of Losartan Potassium/Hydrochlorothiazide 100 mg /25 mg Tablet Under Fed Conditions

Taxi METERS: Measuring Effectiveness of Technology, Education, Referrals and Support

OPtimizing Technology to Improve Medication Adherence and BP Control (OPTIMA-BP)

BRIDGE: Blood Pressure Reduction and Intervention Delivery Via Group Engagement

Eye Drop Application Monitor, Pilot Study

Evaluation of the Safety of Relaxin in Preeclampsia

Groceries for Black Residents of Boston to Stop Hypertension Among Adults Without Treated Hypertension

Renin Profiling in Selection of Initial Antihypertensive Drug

NSAID Use in Postpartum Hypertensive Women

Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE

Salt Study: Inhibited Breathing Pattern and Sodium Inhibitors in Sodium Sensitivity of Blood Pressure

Food Insecurity, Food as Medicine, Hypertension

Measuring Intraabdominal Pressure, Lactic Acid, and Urine Output

Leveraging Electronic Health Record (EHR) Tools to Reduce Health Disparities for Patients With Uncontrolled Hypertension

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

Reshaping Postpartum Follow-up

Aspirin and Preeclampsia

IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure

Dietary Nitrate for Heart Failure

Determinants of Compliance With Glaucoma Therapy

Assessing Alternative Approaches for Blood Pressure Control: A3BC Trial

Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome

Ranolazine and Pulmonary Hypertension